USANA Health Sciences, Inc. (NYSE:USNA) Q3 2023 Earnings Call Transcript

Ivan Feinseth: Well, is there an opportunity for your associates to partner with companies or even doctors who are recommending this to their patients and therefore, monitoring their patients and they are going to as long as they take this, they are going to need to supplement nutrition because if you dramatically cut back your food intake, sadly, you cut out a lot of key nutrients. One of the supposed side effects is muscle loss, obviously, protein, increased protein intake to help counter that. So, the patients that undergo using this are going to be under doctor’s care, but they’re going to need some level of nutritional advisory to, I think, very important component of it, the Nutritional Advisory as part of the overall process of this.

Jim Brown: Yes. No, I would agree with you. And I would say that we do have people in our sales force who have contacts with doctors and/or our doctors, and this would be a great avenue to again help people understand exactly what you are talking about, the effects that it has on your health and that you should be looking at supplementation to counter those effects. Honestly, we haven’t put together a huge strategy and trying to move to go into that area, but it’s something we need to look at. But again, the other thing that will happen is more education will get out there through magazines and other avenues and people will hopefully see that need and seek out better high-quality premium products that we sell at USANA.

Ivan Feinseth: And do you think that part of your thought process is creating a targeted group of your products to address people using these drugs specifically?

Jim Brown: Yes, we can. And we have the ability, like we sell specific kits for different ages and the population itself, we could develop something specifically for that and have it out there to combat that. So again, it’s a great idea, and we have that capability. So we should look at that.

Ivan Feinseth: Thanks. Good luck.

Jim Brown: Thank you.

Doug Hekking: Thanks Ivan.

Operator: There are no further questions. So I’ll hand you back to your host to conclude today’s conference.

Andrew Masuda: Thank you, Valeria, and thanks, everyone, for your questions and for your participation on today’s conference call. If you have any remaining questions, please feel free to contact Investor Relations at (801) 954-7210.

Operator: Thank you for joining today’s call. You may now disconnect.